NASDAQ:DRTS Alpha Tau Medical (DRTS) Stock Forecast, Price & News $3.87 +0.09 (+2.38%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$3.78▼$3.9450-Day Range$2.76▼$3.9852-Week Range$2.75▼$12.50Volume18,562 shsAverage Volume51,883 shsMarket Capitalization$267.53 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Alpha Tau Medical MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside171.3% Upside$10.50 Price TargetShort InterestHealthy0.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.46) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector706th out of 1,018 stocksSurgical & Medical Instruments Industry75th out of 105 stocks 3.5 Analyst's Opinion Consensus RatingAlpha Tau Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.50, Alpha Tau Medical has a forecasted upside of 171.3% from its current price of $3.87.Amount of Analyst CoverageAlpha Tau Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.32% of the float of Alpha Tau Medical has been sold short.Short Interest Ratio / Days to CoverAlpha Tau Medical has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alpha Tau Medical has recently increased by 1.94%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlpha Tau Medical does not currently pay a dividend.Dividend GrowthAlpha Tau Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DRTS. Previous Next 2.3 News and Social Media Coverage News SentimentAlpha Tau Medical has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Alpha Tau Medical this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for DRTS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Alpha Tau Medical to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alpha Tau Medical insiders have not sold or bought any company stock.Percentage Held by Insiders39.50% of the stock of Alpha Tau Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.04% of the stock of Alpha Tau Medical is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alpha Tau Medical are expected to decrease in the coming year, from ($0.46) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alpha Tau Medical is -16.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alpha Tau Medical is -16.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlpha Tau Medical has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alpha Tau Medical (NASDAQ:DRTS) StockAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Read More Receive DRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address DRTS Stock News HeadlinesMay 26, 2023 | americanbankingnews.comAlpha Tau Medical Ltd. to Post FY2023 Earnings of ($0.61) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:DRTS)May 25, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Alpha Tau Medical Ltd (DRTS)May 27, 2023 | Behind the Markets (Ad)AI Creates New Cancer Drug - In Just 30 Days!On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...May 24, 2023 | finance.yahoo.comAlpha Tau Medical to Participate in June Investor ConferencesMay 23, 2023 | msn.comRecap: Alpha Tau Medical Q1 EarningsMay 22, 2023 | finance.yahoo.comShould You Buy Alpha Tau Medical (DRTS) Ahead of Earnings?May 18, 2023 | markets.businessinsider.comAlpha Tau Medical Ltd (DRTS) Receives a Buy from H.C. WainwrightMay 17, 2023 | finance.yahoo.comAlpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge UniversityMay 27, 2023 | Stansberry Research (Ad)Bank Collapse Causes Gold Prices to SoarSilicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.May 17, 2023 | americanbankingnews.comAlpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Down 6.4% in AprilMay 11, 2023 | finance.yahoo.comAlpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network OpenMay 3, 2023 | finance.yahoo.comAlpha Tau Medical to Present at Guggenheim Radiopharmaceuticals DayApril 26, 2023 | americanbankingnews.comAlpha Tau Medical Ltd. (NASDAQ:DRTS) Expected to Earn Q1 2023 Earnings of ($0.05) Per ShareApril 24, 2023 | msn.comAlpha Tau Medical a new buy at HC Wainwright on proprietary radiation therapyApril 24, 2023 | americanbankingnews.comAlpha Tau Medical (NASDAQ:DRTS) Receives New Coverage from Analysts at HC WainwrightMarch 29, 2023 | americanbankingnews.comAlpha Tau Medical (DRTS) and Its Rivals Critical SurveyMarch 26, 2023 | americanbankingnews.comAlpha Tau Medical (DRTS) versus The Competition Head to Head SurveyMarch 24, 2023 | americanbankingnews.comHead to Head Analysis: Alpha Tau Medical (DRTS) and The CompetitionMarch 22, 2023 | americanbankingnews.comAnalyzing Alpha Tau Medical (DRTS) & Its RivalsMarch 21, 2023 | americanbankingnews.comReviewing Alpha Tau Medical (DRTS) and The CompetitionMarch 8, 2023 | finance.yahoo.comAlpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) TrialMarch 1, 2023 | finance.yahoo.comAlpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver MetastasesDecember 13, 2022 | finance.yahoo.comAlpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023November 23, 2022 | finanznachrichten.deAlpha Tau Medical Ltd.: Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 9, 2022 | finance.yahoo.comAlpha Tau to Present at Upcoming November Investor ConferencesOctober 21, 2022 | finance.yahoo.comAlpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation OncologySeptember 24, 2022 | seekingalpha.comDRTS Alpha Tau Medical Ltd.See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DRTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address DRTS Company Calendar Last Earnings3/09/2023Today5/27/2023Next Earnings (Estimated)8/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRTS CUSIPN/A CIK1871321 Webhealthcarecapitalcorp.com Phone972-3577-4115FaxN/AEmployees83Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.50 High Stock Price Forecast$12.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+171.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-15.42% Return on Assets-13.52% Debt Debt-to-Equity RatioN/A Current Ratio18.96 Quick Ratio24.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book2.71Miscellaneous Outstanding Shares69,130,000Free Float41,826,000Market Cap$267.53 million OptionableNot Optionable Beta1.04 Key ExecutivesMr. Uzi Sofer (Age 53)CEO & Chairman Mr. Raphi Levy (Age 38)Chief Financial Officer Mr. Amnon Gat (Age 48)Chief Operations Officer Mr. Ronen Segal (Age 50)Chief Technology Officer Prof. Yona Keisari (Age 76)Chief Scientific Officer & Member of Scientific Advisory board Ms. Rebecca BeckerVP of legalMr. Peter M. Melnyk (Age 61)Chief Commercial Officer Dr. Robert B. Den M.D. (Age 44)Chief Medical Officer & Member of Scientific Advisory Board Prof. Itzhak Kelson (Age 83)Chief Physics Officer & Member of Scientific Advisory Board Ms. Yael Zeiger (Age 40)Corp. Controller More ExecutivesKey CompetitorsSurmodicsNASDAQ:SRDXTELA BioNASDAQ:TELACVRxNASDAQ:CVRXProfound MedicalNASDAQ:PROFPulse BiosciencesNASDAQ:PLSEView All CompetitorsInstitutional OwnershipGeode Capital Management LLCBought 6,364 shares on 5/16/2023Ownership: 0.038%Circle Wealth Management LLCBought 14,500 shares on 5/9/2023Ownership: 0.021%ProVise Management Group LLCBought 35,070 shares on 5/8/2023Ownership: 0.051%ETF Managers Group LLCBought 66,326 shares on 4/18/2023Ownership: 0.096%View All Institutional Transactions DRTS Stock - Frequently Asked Questions Should I buy or sell Alpha Tau Medical stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alpha Tau Medical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRTS shares. View DRTS analyst ratings or view top-rated stocks. What is Alpha Tau Medical's stock price forecast for 2023? 2 brokerages have issued 1 year price objectives for Alpha Tau Medical's shares. Their DRTS share price forecasts range from $9.00 to $12.00. On average, they predict the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 171.3% from the stock's current price. View analysts price targets for DRTS or view top-rated stocks among Wall Street analysts. How have DRTS shares performed in 2023? Alpha Tau Medical's stock was trading at $3.18 at the beginning of 2023. Since then, DRTS stock has increased by 21.7% and is now trading at $3.87. View the best growth stocks for 2023 here. When is Alpha Tau Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 24th 2023. View our DRTS earnings forecast. How were Alpha Tau Medical's earnings last quarter? Alpha Tau Medical Ltd. (NASDAQ:DRTS) announced its earnings results on Thursday, March, 9th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.08. What ETF holds Alpha Tau Medical's stock ? BlueStar Israel Technology ETF holds 66,326 shares of DRTS stock, representing 0.19% of its portfolio. What is Alpha Tau Medical's stock symbol? Alpha Tau Medical trades on the NASDAQ under the ticker symbol "DRTS." Who are Alpha Tau Medical's major shareholders? Alpha Tau Medical's stock is owned by many different retail and institutional investors. Top institutional investors include ETF Managers Group LLC (0.10%), ProVise Management Group LLC (0.05%), Geode Capital Management LLC (0.04%) and Circle Wealth Management LLC (0.02%). How do I buy shares of Alpha Tau Medical? Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alpha Tau Medical's stock price today? One share of DRTS stock can currently be purchased for approximately $3.87. How much money does Alpha Tau Medical make? Alpha Tau Medical (NASDAQ:DRTS) has a market capitalization of $267.53 million. The company earns $-33,760,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. How can I contact Alpha Tau Medical? Alpha Tau Medical's mailing address is 301 N. MARKET STREET STE 1414, WILMINGTON DE, 19801. The official website for the company is healthcarecapitalcorp.com. The company can be reached via phone at 972-3577-4115 or via email at ir@alphatau.com. This page (NASDAQ:DRTS) was last updated on 5/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alpha Tau Medical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.